Bapineuzumab

DB11715

biotech investigational

Deskripsi

Bapineuzumab has been investigated for the treatment of Alzheimer's Disease.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

373 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Bapineuzumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Bapineuzumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Bapineuzumab.
Estrone Estrone may increase the thrombogenic activities of Bapineuzumab.
Estradiol Estradiol may increase the thrombogenic activities of Bapineuzumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Bapineuzumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Bapineuzumab.
Mestranol Mestranol may increase the thrombogenic activities of Bapineuzumab.
Estriol Estriol may increase the thrombogenic activities of Bapineuzumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Bapineuzumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Bapineuzumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Bapineuzumab.
Tibolone Tibolone may increase the thrombogenic activities of Bapineuzumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Bapineuzumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bapineuzumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Bapineuzumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Bapineuzumab.
Zeranol Zeranol may increase the thrombogenic activities of Bapineuzumab.
Equol Equol may increase the thrombogenic activities of Bapineuzumab.
Promestriene Promestriene may increase the thrombogenic activities of Bapineuzumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Bapineuzumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Bapineuzumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Bapineuzumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Bapineuzumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Bapineuzumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Bapineuzumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Bapineuzumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Bapineuzumab.
Formononetin Formononetin may increase the thrombogenic activities of Bapineuzumab.
Estetrol Estetrol may increase the thrombogenic activities of Bapineuzumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Bapineuzumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bapineuzumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Bapineuzumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Bapineuzumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Bapineuzumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bapineuzumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bapineuzumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Bapineuzumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bapineuzumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Bapineuzumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Bapineuzumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Bapineuzumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bapineuzumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bapineuzumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Bapineuzumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bapineuzumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bapineuzumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Bapineuzumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bapineuzumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Bapineuzumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Bapineuzumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Bapineuzumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bapineuzumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bapineuzumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Bapineuzumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Bapineuzumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Bapineuzumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Bapineuzumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Bapineuzumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Bapineuzumab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Bapineuzumab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Bapineuzumab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Bapineuzumab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Bapineuzumab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Bapineuzumab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Bapineuzumab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Bapineuzumab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Bapineuzumab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Bapineuzumab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Bapineuzumab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Bapineuzumab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Bapineuzumab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Bapineuzumab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Bapineuzumab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Bapineuzumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Bapineuzumab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Bapineuzumab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Bapineuzumab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Bapineuzumab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Bapineuzumab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Bapineuzumab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Bapineuzumab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Bapineuzumab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Bapineuzumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Bapineuzumab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Bapineuzumab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Bapineuzumab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bapineuzumab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Bapineuzumab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Bapineuzumab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Bapineuzumab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Bapineuzumab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Bapineuzumab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Bapineuzumab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Bapineuzumab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Bapineuzumab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Bapineuzumab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Bapineuzumab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Bapineuzumab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Bapineuzumab.

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul